The Chemours Company

How this company captures the theme economics

Competitive position

Chemours is a leading global refrigerants producer. Within TSS it maintains a leading position in legacy HFC refrigerants (Freon) and is a front-runner in next-generation low-GWP hydrofluoroolefin (HFO) refrigerants (Opteon), and is the leading supplier of HFO-1234yf used in mobile air conditioning. It competes with Honeywell (Solstice), Arkema, Daikin and lower-cost Chinese fluorochemical producers; Chemours and Honeywell control much of the foundational HFO patent estate, a barrier that supports pricing through the AIM Act transition. Its other segments - Titanium Technologies (Ti-Pure TiO2 pigment) and Advanced Performance Materials (fluoropolymers such as Teflon, Nafion, Viton and Krytox) - are more commoditized and cyclical and were weak in 2025.

Scarce assets

Vertically integrated fluorochemicals manufacturing (fluorspar-to-HF-to-fluoroproducts), a defensible HFO patent portfolio (notably Opteon 1234yf and stationary-AC HFO blends), multi-jurisdiction regulatory registrations and OEM qualifications for low-GWP refrigerants, established Opteon/Freon/FM-200 brands, and access to constrained HFC production quota under the AIM Act. Its refrigerant reclaim/recycling intellectual property and the F-gas Lifecycle Program add a circularity dimension as virgin HFC supply tightens.

Products, segments, and customers

Three reportable segments. TSS ($2.066 billion FY2025 net sales): refrigerants (Opteon HFO, Freon HFC), thermal-management fluids, propellants, foam-blowing agents, specialty solvents and FM-200 fire suppression. Titanium Technologies ($2.429 billion): Ti-Pure titanium-dioxide pigment for coatings, plastics and paper. Advanced Performance Materials ($1.263 billion): fluoropolymers and advanced materials (Teflon PTFE, Nafion, Viton, Krytox) for electronics/semiconductors, hydrogen, coatings and industrial end-markets. Geographies span North America, EMEA, Asia-Pacific and Latin America; customers include HVACR and automotive OEMs, coatings, industrial, electronics and energy.

Theme capture

Chemours captures the cooling-conversion economics primarily by supplying the replacement chemistry the HFC phasedown mandates: Opteon HFO refrigerants and HFO-based blends that displace high-GWP HFCs (e.g. R-410A) as the AIM Act steps down HFC production and consumption. That regulatory tailwind converts into volume and price - Opteon refrigerant net sales rose 56% to $1.264 billion in FY2025 and TSS adjusted EBITDA rose 18% to $670 million, with momentum continuing into Q1 2026 (TSS net sales +22%). On the reclamation side, Chemours addresses the tightening HFC quota through its F-gas Lifecycle Program and HFO reclaim/recycling licensing (including a program with Honeywell), positioning recovered and reclaimed refrigerant as a complementary circular stream - though reclamation is not separately quantified in segment disclosures.

What must be true

1. The AIM Act HFC phasedown and equivalent regimes (EU F-Gas, Kigali Amendment) must keep forcing conversion to low-GWP Opteon at premium economics, sustaining TSS/Opteon volume and pricing rather than triggering rapid price normalization.
2. Chemours must defend its HFO patent and quota position against low-cost entrants (notably Chinese HFO producers) and against illegal HFC imports that would undercut the value of regulated supply.
3. PFAS and environmental litigation/remediation liabilities must stay within reserved and settled bounds and remain fundable from operating cash flow and insurance without impairing the balance sheet or TSS reinvestment.
4. Deleveraging must progress: net leverage (~4.9x at Q1 2026) must trend toward management's stated sub-3.8x-by-2026 and longer-term sub-3x targets via TSS cash generation and asset monetization.

Identifiable catalysts

• Successive AIM Act HFC step-downs (the 2025-2029 stationary-AC transition and further quota cuts) driving continued Opteon volume and price gains.
• Asset monetization and debt paydown (e.g. ~$287 million initial net proceeds from the Kuan Yin TiO2 site sale and a EUR 140 million term-loan repayment in April 2026).
• Progress finalizing and funding PFAS settlements (New Jersey multi-party settlement of ~$875 million over 25 years; a 2026 federal settlement of a $22.5 million penalty plus ~$90 million of remediation) reducing the litigation overhang.
• Execution of 2026 guidance: 3-5% net-sales growth, $800-900 million adjusted EBITDA and free-cash-flow conversion above 25%.

Where the evidence lands

The evidence supports a strong, disclosed link between Chemours and the cooling-conversion theme: the TSS/Opteon franchise is the company's clear earnings engine and a direct beneficiary of the AIM Act HFC phasedown, with record FY2025 segment sales and continued Q1 2026 growth. The equity is best understood as a regulated-tailwind refrigerants franchise bundled with a cyclical TiO2 business and a large, long-dated PFAS liability carried at elevated leverage; the theme exposure is material and improving, while the litigation and balance-sheet risks are the principal offsets. A full assessment of relative value is not possible here without licensed market data. This is an evidence summary, not trading advice.

Next diligence

1. Obtain the FY2025 Form 10-K to extract segment operating income, HFC-quota exposure, the PFAS reserve roll-forward, and total/net debt (not captured as structured metrics in the packet).
2. Model Opteon price/volume durability against HFO patent expiry, Chinese entry and the AIM Act step-down schedule.
3. Quantify the PFAS liability tail (federal MDL, drinking-water, personal-injury) beyond the New Jersey and 2026 federal settlements, and the timing of the ~$150 million insurance and escrow recoveries.
4. Verify the net-leverage trajectory and covenant headroom, and assess whether the reclamation/F-gas Lifecycle Program can become a quantifiable circular revenue stream.